[Amifampridine (Firdapse) for the treatment of Lambert Eaton Myasthenic Syndrome]
Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000700
To assess the efficacy, safety and efficiency of amifampridine as compared to placebo in the treatment of patients with LEMS.
Authors' recommendations: The approval of amifampridine in patients with LEMS is based on previous studies with 3,4-DAP. No additional studies have been carried out for marketing approval. The results indicate that 3,4-DAP in the symptomatic treatment of LEMS at short-term.
Project Status: Completed
Year Published: 2010
URL for published report: http://www.gencat.cat/salut/depsan/units/aatrm/pdf/amifampridina_lambert_eaton_aiaqs2010ca.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Lambert-Eaton Myasthenic Syndrome
Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name: email@example.com / firstname.lastname@example.org
Contact Email: email@example.com / firstname.lastname@example.org
Copyright: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.